Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6151442 | 1.00 | ALDH1A1 (0.43) | ALDH1A1CYP3A4MAPTCYP2D6CA12 | |
| Hydrochloric Acid SCHEMBL6151822 | 0.97 | ALDH1A1 (0.48) | ALDH1A1CYP3A4MAPTCYP2D6CA12 | |
| Hydrochloric Acid SCHEMBL9286549 | 0.97 | ALDH1A1 (0.48) | ALDH1A1CYP3A4MAPTCYP2D6CA12 | |
| Hydrochloric Acid SCHEMBL6151823 | 0.97 | ALDH1A1 (0.48) | ALDH1A1CYP3A4MAPTCYP2D6CA12 | |
| Hydrochloric Acid SCHEMBL9286555 | 0.97 | ALDH1A1 (0.48) | ALDH1A1CYP3A4MAPTCYP2D6CA12 | |
| SCHEMBL22605378 | 0.80 | — | — | |
| SCHEMBL11900824 | 0.71 | — | — | |
| SCHEMBL6151834 | 0.70 | CA12 (0.40) | ALDH1A1CYP3A4MAPTCYP2D6CA12 | |
| Hydrochloric Acid SCHEMBL5444600 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL5444092 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11310565-A | — | — | None | — | — | JP | disclosed |
| US-20200309782-A1 | INTRACELLULAR DELIVERY VEHICLE | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2020-10-01 | — | — | US | disclosed |
| US-10712346-B2 | Intracellular delivery vehicle | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2020-07-14 | — | — | US | disclosed |
| US-20190137503-A1 | INTRACELLULAR DELIVERY VEHICLE | KIRIN KABUSHIKI KAISHA (JP) | 2019-05-09 | — | — | US | disclosed |
| EP-1195376-B1 | Azoamidine compounds and their use as polymerization initiators | WAKO PURE CHEMICAL INDUSTIES L (JP) | 2005-02-02 | — | — | EP | disclosed |
| US-6403774-B1 | WATER SOLUBLE POLYMERIZATION INITIATOR. | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| US-20020062012-A1 | Novel azoamidine compound | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2002-05-23 | — | — | US | disclosed |
| EP-1195376-A1 | Azoamidine compounds and their use as polymerization initiators | Wako Pure Chemical Industies, Ltd. (JP) | 2002-04-10 | — | — | EP | disclosed |
| JP-H11310565-A | NEW AZOAMIDINE COMPOUND | WAKO PURE CHEM IND LTD | 1999-11-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10712346-B2 | Intracellular delivery vehicle | CHERP, ACTB, GOLT1B | ALDH1A1 4647/4885CYP3A4 4860/4885MAPT 1992/4885 |
| US-20200309782-A1 | INTRACELLULAR DELIVERY VEHICLE | CHERP, ACTB, GOLT1B | ALDH1A1 4647/4885CYP3A4 4860/4885MAPT 1992/4885 |
| US-20190137503-A1 | INTRACELLULAR DELIVERY VEHICLE | CHERP, ACTB, GOLT1B | ALDH1A1 4647/4885CYP3A4 4860/4885MAPT 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.